The effect of miswak containing dentifrice in the management of periodontal disease in postmenopausal women.
- Conditions
- Health Condition 1: N958- Other specified menopausal and perimenopausal disorders
- Registration Number
- CTRI/2023/07/055572
- Lead Sponsor
- ABIRAMI J
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
2.Self-reported history of menopause with the history of cessation of menstrual cycle over 12months (WHO)
According to AAP 2017 classification the following criteria were taken into consideration for evaluation of patients with Stage III periodontitis
1.Patients above 54years of age.
2.Patients using tobacco of any form.
3.Patients with immunodeficiency disorders.
4.Patients with other systemic inflammatory conditions like sepsis, pneumonia, pleural effusion, intra-abdominal infections, inflammatory bowel disorders, inflammatory rheumatoid disorders, chronic kidney disease, cancers, diabetes, COPD, asthma, HIV and hepatitis will be excluded from the study.
5.History of periodontal treatment within the previous 6 months.
6.History of antibiotic therapy in the past 3 months.
7.Subjects who are not willing to participate in the study.
8.Patients on HRT.
9.Patients with a history of hysterectomy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method to evaluate clinical parameters <br/ ><br>and IL6Timepoint: BASELINE AND 6 MONTHS
- Secondary Outcome Measures
Name Time Method TO COMPARE AND CORRELATE THE IL6 LEVELS AND OSTEOCALCIN LEVELS IN POST MENOPAUSAL WOMEN USING A DENTIFRICE WITH AND WITHOUT MISWAK AS AN INGREDIENTTimepoint: 3MONTHS AND 6MONTHS